P3C541b

P3C541b is an investigational lipopeptide immunotherapeutic developed for use in HIV-seropositive patients. It was evaluated in a Phase I clinical trial to assess its safety and immunogenicity when administered subcutaneously. Lipopeptides are molecules consisting of a lipid connected to a peptide, and they can act as potent immune modulators or antimicrobial agents. The mechanism of action for lipopeptide immunotherapeutics like P3C541b typically involves stimulating the immune system, potentially by mimicking pathogen-associated molecular patterns that activate innate and adaptive immunity. The specific mechanism of action for P3C541b in HIV therapy has not been fully detailed in public sources, but it is designed as an immunotherapeutic rather than an antibiotic[1][2][3].

Other names

UBI HIV LipopeptideP3C541b lipopeptideP-3C541b lipopeptideP 3C541b lipopeptideUBI HIV-1 lipopeptide immunotherapeutic